Urobak100 ml

Urobak 100 ml is specifically indicated for the treatment & prophylaxis of urinary tract infections caused by susceptible strains of Escherichia coli, Enterococci, Staphylococcus aureus, Staphylococcus saprophyticus and certain susceptible strains of Klebsiella and Enterobacter species.

Systemic Urinary Anti- infective

Urobak 100 ml interferes with cell metabolism and cell wall synthesis by inhibiting several enzyme systems including acetyl coenzyme A. It is bactericidal to most gram-positive and gram-negative urinary tract pathogens.

Urobak 100 ml tablet (In adults): Uncomplicated urinary tract infections: 50-100 mg four times a day- the lower dosage level is recommended. Therapy should be continued for one week or for at least 3 days after sterility of the urine is obtained. For long-term suppressive therapy: In adults, a reduction of dosage to 50-100 mg at bedtime may be adequate. Urobak 100 ml capsule (In adults): Acute Uncomplicated Urinary Tract Infections (UTIs): 50 mg four times daily for 7 days. Long term suppression: 50-100 mg once a day. Prophylaxis: 50 mg four times daily for the duration of procedure and for three days thereafter. Urobak 100 ml SR capsule: Adults and Children over 12 years: One 100 mg capsule every 12 hours for seven days. Genito-urinary surgical prophylaxis: One capsule twice daily on day of procedure and for next 3 days. Urobak 100 ml suspension: Children: 5-7 mg/kg/day in four divided doses (contraindicated under one month of age). The average dose of Nintoin suspension for pediatric patients are as follows- 7 to 11 kg: ½ (2.5 ml) teaspoonfuls 4 times daily. 12 to 21 kg: 1 (5 ml) teaspoonfuls 4 times daily. 22 to 30 kg: 1½ (7.5 ml) teaspoonfuls 4 times daily. 31 to 41 kg: 2 (10 ml) teaspoonfuls 4 times daily. Therapy should be continued for one week or for at least 3 days after sterility of the urine is obtained. For long-term suppressive therapy in children, doses as low as 1 mg/kg per 24 hours, given in a single dose or in two divided doses, may be adequate.

Urobak 100 ml should be taken with food.

Antacids containing Magnesium Trisilicate, when administered concomitantly with Urobak 100 ml, reduce both the rate and extent of absorption of Uricosuric drugs, such as Probenecid and Sulfinpyrazone, can inhibit renal tubular secretion of Urobak 100 ml.

Anuria, oliguria or significant impairment of renal function are contraindications. This drug is contraindicated in pregnant patients at 38-42 weeks, during labor and delivery. Urobak 100 ml is also contraindicated in those patients with known hypersensitivity to Urobak 100 ml.

The most frequent clinical adverse events are nausea, headache, and flatulence. Other less occurred adverse events are diarrhea, dyspepsia, abdominal pain, constipation, emesis, dizziness and drowsiness.

Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed.Urobak 100 ml has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from Urobak 100 ml in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

If acute, sub-acute or chronic pulmonary reactions occur, Urobak 100 ml should be discontinued. Antacid preparations containing magnesium trisilicate should not be taken while taking Urobak 100 ml.

Occasional incidents of acute overdosage of Urobak 100 ml have not resulted in any specific symptoms other than vomiting. Induction of emesis is recommended.

Do not store above 30°C. Keep away from light and out of the reach of children.

Systemic Urinary Anti- infective

Urobak 100 ml is an antibacterial agent specific for urinary tract infections. Urobak 100 ml is highly soluble in urine, to which it may impart a brown color. Urobak 100 ml inactivates or alters bacterial ribosomal proteins and other macromolecules. Urobak 100 ml has been shown to be active against the following bacteria: Gram-Positive Aerobes Staphylococcus saprophyticus, Coagulase-negative staphylococci (including Staphylococcus epidermidis), Enterococcus faecalis, Staphylococcus aureus, Streptococcus agalactiae, Group D streptococci, Viridans group streptococci. Gram-Negative Aerobes- Escherichia coli, Citrobacter amalonaticus, Citrobacter diversus, Citrobacter freundii, Klebsiella oxytoca, Klebsiella ozaenae.

Pregnancy Category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Urobak 100 ml has been detected in human breast milk in trace amounts. Because of the potential for serious adverse reactions from Urobak 100 ml in nursing infants under one month of age, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.